Imaging built for early decisions.
We embed imaging into scientific decision-making from the outset, not as a procedural service, but as an active input into your development strategy.
Science-led design
Imaging strategy aligned with biological questions and decision points, not just endpoints to report.
Real-time visibility
Live access to imaging data, annotations and analyses throughout the study lifecycle via Aperis.
Scientific integrity
We provide honest, objective feedback, including when findings are uncomfortable. Better decisions require clarity, not reassurance.
Augmented endpoints
Novel and additive imaging measures that go beyond standard endpoints to characterise treatment response more completely.
From study design
to final report.
We provide comprehensive imaging support across the full lifecycle of early clinical development, with a focus on studies where imaging insight directly informs strategy.
Aligning imaging strategy with biological questions.
Developing and reviewing imaging charters and manuals.
Identifying and qualifying high-quality imaging sites.
Training and supporting imaging sites throughout the trial.
Standardizing image collection processes.
Securely managing data through a digital platform.
Reviewing and interpreting data by specialists.
Providing clear and comprehensive reports for decision-making.
Aligning imaging strategy with biological questions.
Developing and reviewing imaging charters and manuals.
Identifying and qualifying high-quality imaging sites.
Training and supporting imaging sites throughout the trial.
Standardizing image collection processes.
Securely managing data through a digital platform.
Reviewing and interpreting data by specialists.
Providing clear and comprehensive reports for decision-making.
Fidēs brings deep scientific knowledge and a growing KOL network to each therapeutic area. Natively strong in GI, and expanding across oncology and beyond.
Gastroenterology
IBD, motility, hepatic disease
Oncology
Solid tumours, response assessment
Women’s Health
Uterine Motility, Endometriosis, Adenomyosis, Uterine and Cervical Cancer, PMOS and infertility
Rheumatology
Neurology, neurodegeneration
Systemic and Chronic
CKD, renal function
Transparency by design.
Aperis is our proprietary, web-native imaging workflow platform built to support scientific decision-making in early development. Most imaging platforms move data from A to B. Aperis was designed for how scientists actually interrogate imaging while studies are still evolving.
-
Real-time data visibility Sponsors access imaging data, annotations and analyses continuously, not only at formal reporting milestones.
-
Collaborative review environment Multi-modality side-by-side image review with embedded workflows and direct sponsor access.
-
Rapid study setup Standard studies configured within one day, complex studies within days, not weeks.
-
Adaptive imaging support Designed for live studies where strategy may need to evolve as data emerges.
Gastroenterology
Gastroenterology The Role of Movement in Characterising Treatment Response in IBD
Augmenting standard MRI endpoints with motility measures to deliver a more complete characterisation of biological response in Crohn's disease.
Read case study
Gastroenterology The Power of Movement: Motion as an Imaging Endpoint
Augmenting standard MRI endpoints with motility measures to deliver a more complete characterisation of biological response in Crohn's disease.
Read case study
Gastroenterology Structural and Functional MRI Assessment in Post-Surgical J-Pouch Patients
Combining structural and functional MRI to characterise pouch function and inflammation in post-surgical J-pouch patients.
Read case study
Oncology Uterine Contractility as a Quantitative Endpoint in Early-Phase Gynaecology Trials
Establishing uterine contractility as a quantitative, reproducible imaging endpoint for early-phase gynaecology trials.
Read case study
Oncology Beyond RECIST: Additive Imaging Endpoints in Solid Tumour Trials
How augmented endpoint analysis provides earlier and more interpretable signals than standard volumetric measures alone.
Read case study
Oncology Live Data Visibility in Phase I Imaging Trials
A review of how real-time imaging access changes sponsor behaviour and supports earlier go / no-go decisions in early development.
Read case study
Gastroenterology Augmented MRI Endpoints in a Phase II Crohn’s Program
Adding functional motility metrics to a Phase II Crohn's imaging protocol to sharpen the read on treatment response.
Read case study
Gastroenterology Cine-MRI Motility Analysis as a Primary Endpoint
Using cine-MRI motility analysis as a primary endpoint to detect functional change earlier than structural measures alone.
Read case studyBuilt from Motilent’s platform and science.
Years of GI imaging science from Motilent
Research projects and clinical trials on the platform
Listed imaging platform: EntrolyticsMD
Therapy areas supported across the Fidēs network
Fidēs is a spin-out from Motilent — a medical imaging software company with over a decade of focused work on quantitative GI imaging, proprietary motion analysis tools and a platform used across more than 500 research projects and clinical trials globally.
That foundation gives Fidēs a mature, clinically validated technology base in Aperis, and native scientific depth in gastroenterology and hepatology. It also gives us a network of leading KOLs who contribute to study design, endpoint development and scientific oversight across therapy areas.
Fidēs is independent and therapy-agnostic. Our focus extends across oncology, cardiovascular, CNS, renal and metabolic disease, with scientific fit, not inherited specialism, guiding where we work.